Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Trump sets fundraising record with $50.5M from Florida eventChinese vice premier stresses deepening SOE reformPreserving worldPitt modernized its offense over the winter. The growing pains will be felt for a whileCapitals' Nick Jensen is conscious and alert after being stretchered off the iceCam Rising plays in Utah's spring football game after missing 2023 season with knee injuryChina's State Council stresses efforts in flood relief, reconstructionMainland spokesperson rebukes DPP for selling out Taiwan peopleChinese premier stresses boosting highSenior CPC official meets Macao media delegation
1.8983s , 5260.2265625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Planet Panorama news portal